Up­dat­ed: Two years on from con­fir­ma­to­ry tri­al halt, FDA sub­mits more ques­tions to On­copep­tides over Pepax­to with­draw­al

Fol­low­ing up on last week’s meet­ing on FDA’s long-await­ed pro­pos­al to with­draw the ac­cel­er­at­ed ap­proval for On­copep­tides’ blood can­cer drug Pepax­to (mel­pha­lan flufe­namide), the FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER